Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1.Chronic hepatitis B.(Hepatitis B surface antigen positive for more than 6 months or having evidence of chronic hepatitis B virus infection).~* 2.Defined by an acute deterioration in transaminase greater than or equal to 5 times upper normal limit over14 days.~* 3.Development of jaundice (serum bilirubin greater than or equal to 10mg/dl).~* 4.Development of coagulopathy(PTA≤40% or INR≥1.5 ).~* More than one of the 5-8 criteria：~* 5.Development of hepatic encephalopathy.~* 6.Development of hepatorenal syndrome.~* 7.Hepatic narrowing progressively.~* 8.Development of massive ascites or peritonitis.~* 9. Willing to provide informed consent and comply with the test requirements~Exclusion Criteria:~* 1.Patients who have hepatocellular carcinoma confirmed by ultrasound/CT/MR.~* 2.Patients who have autoimmune disease (such as inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, etc ) or with abnormal elevation level of autoimmune antibody.~* 3.Model for end-stage liver disease (MELD) score \<17 or \>35.~* 4.Patients with significant co-morbid illnesses such as cardiovascular or respiratory or intrinsic renal diseases which by themselves may have a bearing on the outcome.~* 5.Patients with diseases that researchers consider inappropriate to participate in the study.~* 6.Patients who have disseminated intravascular coagulation.~* 7.Drug allergy.~* 8.Patients with any other contraindications to thymosin alpha1.~* 9.Patients who participated in other clinical trials at the same time.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin-α1 group (Type: EXPERIMENTAL): Patients receive treatment based on standard Therapy with additional Thymosin-α1
- control group (Type: NO_INTERVENTION): Patients receive treatment based on standard Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).